These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

917 related articles for article (PubMed ID: 35006032)

  • 41. IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.
    Ng BD; Rajagopalan A; Kousa AI; Fischman JS; Chen S; Massa A; Elias HK; Manuele D; Galiano M; Lemarquis AL; Boardman AP; DeWolf S; Pierce J; Bogen B; James SE; van den Brink MRM
    Blood; 2024 Jul; 144(2):171-186. PubMed ID: 38579288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
    Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
    Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
    Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective anti-BCMA retreatment in multiple myeloma.
    Gazeau N; Beauvais D; Yakoub-Agha I; Mitra S; Campbell TB; Facon T; Manier S
    Blood Adv; 2021 Aug; 5(15):3016-3020. PubMed ID: 34351389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody-Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
    Ray U; Orlowski RZ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-BCMA novel therapies for multiple myeloma.
    Sammartano V; Franceschini M; Fredducci S; Caroni F; Ciofini S; Pacelli P; Bocchia M; Gozzetti A
    Cancer Drug Resist; 2023; 6(1):169-181. PubMed ID: 37065871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.
    Shrivastava T; Van Rhee F; Al Hadidi S
    Onco Targets Ther; 2023; 16():441-464. PubMed ID: 37359353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma.
    Chekol Abebe E; Yibeltal Shiferaw M; Tadele Admasu F; Asmamaw Dejenie T
    Front Immunol; 2022; 13():991092. PubMed ID: 36119032
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth.
    Sun F; Cheng Y; Wanchai V; Guo W; Mery D; Xu H; Gai D; Siegel E; Bailey C; Ashby C; Al Hadidi S; Schinke C; Thanendrarajan S; Ma Y; Yi Q; Orlowski RZ; Zangari M; van Rhee F; Janz S; Bishop G; Tricot G; Shaughnessy JD; Zhan F
    Nat Commun; 2024 Jan; 15(1):615. PubMed ID: 38242888
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Plasma levels of BCMA-positive extracellular vesicles correlate to response and side effects in myeloma patients treated with belantamab-mafodotin.
    Springer C; Krauter J; Trummer A
    Oncotarget; 2023 Dec; 14():949-956. PubMed ID: 38039414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
    Wu JF; Dhakal B
    J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Idecabtagene vicleucel for relapsed/refractory multiple myeloma: a review of recent advances.
    Tu W; Xiao Y; Wang Y; Luo R; Chen ZS
    Drugs Today (Barc); 2022 Mar; 58(3):117-132. PubMed ID: 35274631
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
    Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
    Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
    [No Abstract]   [Full Text] [Related]  

  • 54. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
    Feng D; Sun J
    Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma.
    Fang J; Zhou F
    Ann Hematol; 2024 Apr; 103(4):1069-1083. PubMed ID: 37704875
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
    Ma T; Shi J; Liu H
    Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma.
    Zah E; Nam E; Bhuvan V; Tran U; Ji BY; Gosliner SB; Wang X; Brown CE; Chen YY
    Nat Commun; 2020 May; 11(1):2283. PubMed ID: 32385241
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapeutic strategies targeting B cell maturation antigen in multiple myeloma.
    Fang Y; Hou J
    Mil Med Res; 2021 Jan; 8(1):9. PubMed ID: 33504363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.
    Anderson LD
    Future Oncol; 2022 Jan; 18(3):277-289. PubMed ID: 34854741
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.